

Clean Version of Amended Claims
Pursuant to 37 C.F.R. § 1.121(c)(1)(ii)

- Sub
J1
1. A method for designing a compound specifically inhibiting targeted ribonucleic acid function comprising the steps of:
 - (a) determining the nucleotide sequence in the targeted ribonucleic acid that is critical to function;
 - (b) determining the secondary structure of the region of the targeted ribonucleic acid in which the critical site is located;
 - (c) determining the three-dimensional structure of the targeted RNA, including the position of the critical site relative to the major and minor grooves;
 - (d) determining the sequence of nucleotides and structure flanking the critical site in the targeted ribonucleic acid that is specific to the critical region of the ribonucleic acid to be inhibited and within the minor groove; and
 - (e) synthesizing a compound that will bind specifically to the critical site within the minor groove of the targeted ribonucleic acid thereby inhibiting targeted ribonucleic acid function.
 3. The method of claim 1 wherein the ribonucleic acid is selected from the group consisting of mRNA, rRNA, tRNA and viral RNA.
 4. The method of claim 1 wherein inhibition of targeted ribonucleic acid function inhibits protein synthesis.
 5. The method of claim 4 wherein protein synthesis is inhibited in cells selected from the group consisting of tumor cells, virally infected cells, and bacterial cells.
 6. The method of claim 1 wherein the three-dimensional structure is modeled using sequences of the RNA and calculating the minimum energies for these structures.

7. The method of claim 1 wherein the critical region of the targeted ribonucleic acid is determined by mutation of regions of the targeted RNA and comparison of the function of the mutated RNA with the original RNA, wherein mutations that result in mutant RNA having altered function indicate that the site of mutation is a critical site.

8. The method of claim 1 wherein the targeted RNA is a tRNA, wherein the critical region of the tRNA is determined by site directed mutation of the tRNA and analysis of the function of the mutated tRNA.

9. The method of claim 1 further comprising determining an effective amount of the compound and combining the compound with a pharmaceutical carrier.

10. The method of claim 9 wherein the carrier is selected from the group consisting of pharmaceutically acceptable compositions for topical administration, pharmaceutically acceptable compositions for parenteral administration, pharmaceutically acceptable compositions for enteral administration, and combinations thereof.

11. A complementary compound comprising hydrogen bond donor and acceptor sites arranged to specifically bind and inhibit the function of a targeted RNA molecule, wherein the compound is specifically directed to and binds to a critical region of the RNA molecule, located within the minor groove of the RNA molecule, identified by a combination of the primary, secondary and tertiary structure of the critical region.

12. The complementary compound of claim 11 wherein the RNA is selected from the group consisting of mRNA, tRNA, rRNA, and viral RNA.

13. The complementary compound of claim 11 further comprising a pharmaceutically acceptable carrier selected from the group consisting of pharmaceutically acceptable compositions for topical administration, pharmaceutically acceptable compositions for parenteral

~~12~~ administration, pharmaceutically acceptable compositions for enteral administration, and combinations thereof.

SUB
J1
14. The method of claim 3 wherein the critical site is in the minor groove of the acceptor stem of a tRNA molecule.

15. The method of claim 14 wherein the tRNA molecule is tRNA^{Ala}.

16. The method of claim 15 wherein the critical site is the G3:U70 base pair.

SUB
J1
I3
17. The complementary compound of claim 12 wherein the compound binds to a critical region within the minor groove of the acceptor stem of a tRNA molecule.

18. The complementary compound of claim 17 wherein the tRNA molecule is tRNA^{Ala}.

19. The complementary compound of claim 17 wherein the critical region is the G3:U70 base pair.

SUB
J1
20. The method of claim 1 wherein the compound is a nucleic acid and the compound is synthesized *in vivo* from a retroviral vector.

I4 SUB
J1
21. The complementary compound of claim 11 wherein the compound is a nucleic acid and the compound is synthesized *in vivo* from a retroviral vector.